Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer

Sabina Luszczak; Benjamin S. Simpson; Urszula Stopka-Farooqui; Vignesh Krishna Sathyadevan; Lina M. Carmona Echeverria; Christopher Kumar; Helena Costa; Aiman Haider; Alex Freeman; Charles Jameson; Susan Heavey

doi:https://doi.org/10.1038/s41598-020-71263-9

doi.org/10.1038/s41598-020-71263-9

Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer

,

,

..., Susan Heavey

14

Scientific Reports4.60

Volume: 10, Issue: 1

Published: Sep 1, 2020

Abstract

PIM and PI3K/mTOR pathways are often dysregulated in prostate cancer, and may lead to decreased survival, increased metastasis and invasion. The pathways are heavily interconnected and act on a variety of common effectors that can lead to the development of resistance to drug inhibitors. Most current treatments exhibit issues with toxicity and resistance. We investigated the novel multikinase PIM/PI3K/mTOR inhibitor, AUM302, versus a combination...

Paper Fields

Paper Details

Title

Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer

DOI

doi.org/10.1038/s41598-020-71263-9

Published Date

Sep 1, 2020

Journal

Scientific Reports

Volume

10

Issue

1

Citation AnalysisPro

You’ll need to upgrade your plan to Pro

Looking to understand the true influence of a researcher’s work across journals & affiliations?

Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.

Learn more

Notes

History